课题基金 / 基金详情

项目摘要

项目成果

MARTIN G SANDA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):尽管血清前列腺特异性抗原(PSA)被广泛使用,但作为前列腺癌生物标记物的准确性有限,需要新的生物标记物来改进侵袭性前列腺癌的早期发现。通过前列腺癌生物标记物开发方面的合作,聚集在这里的研究人员已经确定了前列腺癌早期检测的途径,这是基于α-甲基酰基辅酶A消旋酶(AMACR)在癌组织(但不是正常前列腺组织)中表达的生物学后果。初步数据表明,前列腺癌患者外周血中循环抗AMACR自身抗体的检出率高于对照组患者。此外,我们观察到,具有侵袭性病理特征的癌症患者的血清中抗AMACR自身抗体效价高于更具惰性前列腺癌的患者。为了建立在这些初步数据的基础上,我们组建了一个多学科、多机构的研究团队,在4个机构(贝丝以色列女执事医疗中心、布里格姆和妇女医院、Dana Farber癌症研究所和密歇根大学)建立了一个中心,用于对这种AMACR靶向以及其他候选的新型前列腺癌生物标记物进行临床验证。这一建议的基本假设是,对AMACR的体液免疫反应(作为与前列腺癌相关的AMACR表达的各种临床指标的原型)与前列腺癌的存在和严重程度显著相关,并为前列腺癌的早期发现提供了机会。这一假设将通过评估从三个互补的临床队列收集的血清来解决。这些队列中的每一个都在评估三个目标方面提供了互补的优势和局限性,这三个目标共同解决了如下研究假设: 1.在接受前列腺活检的男性前瞻性病例对照队列中,比较抗AMACR抗体存在的特异性和PSA检测前列腺癌的特异性。将为此目的登记1800例活组织检查。 2.在医生健康研究队列中,验证针对包括AMACR在内的组织生物标记物的体液反应在检测癌症和测量癌症严重程度方面的准确性。该队列是一个基于社区的前列腺癌和非前列腺癌医生队列。将对500例前列腺癌病例和1500例对照进行评估,以实现这一目标。 3.评估抗AMACR抗体或存在针对前列腺组织生物标志物的其他体液反应是否可以区分前列腺癌和早期癌症,在接受前列腺癌治疗的男性队列中,前列腺癌向外扩散的风险较低。将为此目的对1500例前列腺癌病例进行评估。 我们将从3个AIMS加在一起的总计4700名受试者的外周血液和相关临床信息中收集,并将这些样本扩展到EDRN的其他合作生物标记物研究。
英文摘要
DESCRIPTION (provided by applicant): Despite its widespread use, serum Prostate-Specific Antigen (PSA) has limited accuracy as a prostate cancer biomarker, and new biomarkers are needed to improve early detection of aggressive prostate cancers. Through a collaborative effort in prostate cancer biomarker development, investigators assembled herein have identified avenues for prostate cancer early detection based on biological consequences of alpha-methylacyl-CoA racemase (AMACR) expression in cancerous, but not normal, prostate tissue. Preliminary data indicate that circulating anti-AMACR autoantibodies are detectable in the peripheral blood of prostate cancer patients at higher rates than among control patients. Moreover, we observed higher anti-AMACR auto-antibody titers in sera of patients that had cancers with aggressive pathological features than among patients with more indolent prostate cancer. To build upon these preliminary data, we have assembled a multi-disciplinary, multi-institutional team of investigators to establish a center for the clinical validation of such AMACR-targeted as well as other candidate novel prostate cancer biomarkers at 4 institutions (Beth Israel-Deaconess Medical Center, Brigham and Women's Hospital, Dana Farber Cancer Institute, and the University of Michigan). The primary hypothesis of this proposal is that a humoral immune response to AMACR (as a prototype of various clinical measures related to prostate cancer-associated AMACR expression) is significantly associated with presence and severity of prostate cancer, and provides an opportunity for improvements in early detection of prostate cancer. This hypothesis will be addressed through evaluation of serum collected from three complementary clinical cohorts. Each of these cohorts provides complementary strengths and limitations in evaluating three aims that together address the study hypothesis as follows: 1. To compare specificity of anti-AMACR antibody presence to the specificity of PSA for detecting prostate cancer in a prospective case-control cohort of men undergoing prostate biopsy. 1800 biopsy cases will be enrolled for this Aim. 2. To validate the accuracy of humoral responses against tissue biomarkers, including AMACR, in detecting cancers and gauging cancer severity in the Physicians' Health Study cohort, a community-based cohort of physicians with and without prostate cancer. 500 prostate cancer cases and 1500 controls will be evaluated for this Aim. 3. To evaluate whether anti-AMACR antibody or presence of other humoral responses against prostatic tissue biomarkers) can distinguish aggressive prostate cancers from early cancers at lower risk for extra-prostatic spread in a cohort of men treated for prostate cancer. 1500 prostate caner cases will be evaluated for this Aim. We will collect peripheral blood and relevant clinical information from an aggregate total of 4700 subjects between the 3 Aims combined, and will extend these specimens for other, collaborative biomarker studies of the EDRN.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer
Effectiveness of Robotic Compared to Standard Prostatectomy for Prostate Cancer
University of Michigan O'Brien Center for Urology Research
University of Michigan O'Brien Center for Urology Research
海外基金